This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Escitalopram in the Treatment of Internet Addiction

This study has been completed.
Forest Laboratories
Information provided by:
Icahn School of Medicine at Mount Sinai Identifier:
First received: November 28, 2007
Last updated: May 23, 2008
Last verified: May 2008
The purpose of this study was to determine whether Lexapro (Escitalopram) is safe and effective in treating problematic internet use.

Condition Intervention Phase
Internet Addiction Drug: Escitalopram Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of Escitalopram in the Treatment of Internet Addiction

Resource links provided by NLM:

Further study details as provided by Icahn School of Medicine at Mount Sinai:

Primary Outcome Measures:
  • length of non-essential Internet use in hours/week as well as CGI-Improvement [ Time Frame: baseline and biweekly for 10 weeks ]

Secondary Outcome Measures:
  • ratings on depression, anxiety, impulsivity, self-esteem, obsessive-compulsive symptoms [ Time Frame: baseline and biweekly for 10 weeks ]

Enrollment: 31
Study Start Date: December 2002
Study Completion Date: October 2004
Arms Assigned Interventions
Experimental: Single Arm
Drug: Escitalopram
10 mg/day
Other Name: Lexapro

Detailed Description:
Many individuals experience marked distress and functional impairments as a result of their perceived inability to control their 'non-essential' (non-job/school related) use of the Internet. Frequently these people develop a preoccupation with the Internet, a need for escape to the Internet, and increasing irritability when trying to cut back use of the Internet. There have been no studies to date looking at the effectiveness of medications in the treatment of this disorder. In our clinical experience, we find these patients with Internet addiction usually respond to serotonin reuptake inhibitors within 12 weeks. This study will examine the efficacy of escitalopram in Internet addiction among adults.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject has signed an informed consent form
  2. Current diagnosis of Internet addiction
  3. Age ³ 18
  4. Subject must be able to take oral medication
  5. Subject may be in psychotherapy initiated at least three months prior to Screening. Subject must not discontinue or otherwise alter this therapy during the study.
  6. In the opinion of the investigator, the subject is capable of complying with all study procedures.

Exclusion Criteria:

  1. Current suicidal or homicidal ideation
  2. Subject has a primary diagnosis of schizophrenia or other psychotic disorders
  3. Subject has a primary diagnosis of Bipolar I disorder
  4. Current pedophilia
  5. Current DSM-IV diagnosis of substance dependence or abuse, excluding nicotine
  6. Women of child-bearing potential who are pregnant, nursing, or not using contraception
  7. Use of antidepressants at a therapeutic level for the treatment of problematic internet use within 2 weeks prior to study entry (or 4 weeks for use of MAOIs, or 6 weeks for use of fluoxetine)
  8. Current use of antidepressants at a therapeutic level for the treatment of a disorder other than problematic internet use
  9. Subject has any organic mental disorder
  10. Clinically significant unstable medical disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00565422

Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Forest Laboratories
Principal Investigator: Eric Hollander, MD Icahn School of Medicine at Mount Sinai
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Eric Hollander, Mount Sinai School of Medicine Identifier: NCT00565422     History of Changes
Other Study ID Numbers: LXP-MD-09
Study First Received: November 28, 2007
Last Updated: May 23, 2008

Keywords provided by Icahn School of Medicine at Mount Sinai:
Internet addiction
Problematic internet use

Additional relevant MeSH terms:
Behavior, Addictive
Compulsive Behavior
Impulsive Behavior
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents processed this record on September 21, 2017